Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386073 | 0.84 | PIK3CA (0.52) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL26977981 | 0.84 | PIK3CA (0.49) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL30559716 | 0.84 | PIK3CA (0.49) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL6169125 | 0.79 | ALDH1A1 (0.58) | PIK3CAALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL6265152 | 0.78 | KMT2A (0.55) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL21380007 | 0.76 | ADORA2A (0.46) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL12935066 | 0.76 | LMNA (0.50) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL1275731 | 0.76 | ALDH1A1 (0.48) | PIK3CAALDH1A1MAPTLMNAMPO | |
| SCHEMBL24460959 | 0.75 | LMNA (0.43) | PIK3CAALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL31511602 | 0.75 | ALDH1A1 (0.40) | PIK3CAALDH1A1MAPTLMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| CN-115279766-B | Combination therapy comprising A2A/A2B and a PD-1/PD-L1 inhibitor | 因赛特公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-01-30 | — | — | US | disclosed |
| CN-112384515-B | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117500503-A | Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody | 因赛特公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2021138512-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
| EP-3810610-A1 | FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021041360-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041360-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061809-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-20210061809-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | PIK3CA 606/4885ALDH1A1 459/4885MAPT 3389/4885 |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | PIK3CA 953/4885ALDH1A1 565/4885MAPT 3580/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | PIK3CA 953/4885ALDH1A1 565/4885MAPT 3580/4885 |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | PIK3CA 314/4885ALDH1A1 347/4885MAPT 3697/4885 |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | PIK3CA 314/4885ALDH1A1 347/4885MAPT 3697/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | PIK3CA 2363/4885ALDH1A1 187/4885MAPT 4485/4885 |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | PIK3CA 475/4885ALDH1A1 498/4885MAPT 3147/4885 |
| US-20210061809-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | PIK3CA 475/4885ALDH1A1 498/4885MAPT 3147/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | PIK3CA 314/4885ALDH1A1 347/4885MAPT 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.